Treatment in Juvenile Scleroderma
Purpose of Review Treatment of scleroderma in children is challenging since little is known about its pathogenesis. Herein, we review the most recent evidence regarding the treatment of juvenile scleroderma. Recent Findings According to the recent recommendations for Pediatric Rheumatology in Europe...
Gespeichert in:
| Veröffentlicht in: | Current rheumatology reports 2020-08, Vol.22 (8), p.45-45, Article 45 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 45 |
|---|---|
| container_issue | 8 |
| container_start_page | 45 |
| container_title | Current rheumatology reports |
| container_volume | 22 |
| creator | Zulian, Francesco Tirelli, Francesca |
| description | Purpose of Review
Treatment of scleroderma in children is challenging since little is known about its pathogenesis. Herein, we review the most recent evidence regarding the treatment of juvenile scleroderma.
Recent Findings
According to the recent recommendations for Pediatric Rheumatology in Europe (SHARE), systemic treatment in localized scleroderma is needed when there is a risk for disability, such as in generalized or pansclerotic morphea and progressive linear scleroderma. In juvenile systemic sclerosis, the introduction of the severity score, J4S, has standardized the assessment of the patients in the daily practice and allowed a more tailored therapeutic approach. Since, to date, no clinical trial is available in JSSc, due to its rarity, the treatment is based on adults’ experience.
Summary
The recent recommendations for juvenile scleroderma represent an important instrument to standardize the treatment approach, confirm the role of methotrexate, and open new windows for effective experimental treatments, such as mycophenolate mofetil and biological agents, for severe or refractory cases. |
| doi_str_mv | 10.1007/s11926-020-00910-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2418125759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2418125759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-d1272bcfb930d6b81c911660300efcb1687252f651f2de0870ab1c3c2f3acfc13</originalsourceid><addsrcrecordid>eNp9kLtOxDAQRS0EEsvCD1CFjsYwYyd2UqIVT61EwVJbjjNGWeWx2Ala_p4soaaaKc650r2MXSLcIIC-jYiFUBwEcIACge-P2AIzmXIlQR8ffiG51Do9ZWcxbmEiIZcLdrUJZIeWuiGpu-Rl_KKubih5cw2FvqLQ2nN24m0T6eLvLtn7w_1m9cTXr4_Pq7s1d1KkA69QaFE6XxYSKlXm6ApEpUACkHclqlyLTHiVoRcVQa7BluikE15a5x3KJbuec3eh_xwpDqato6OmsR31YzQixRxFprNiQsWMutDHGMibXahbG74NgjnsYeY9zNTS_O5h9pMkZylOcPdBwWz7MXRTpf-sH0LOYho</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2418125759</pqid></control><display><type>article</type><title>Treatment in Juvenile Scleroderma</title><source>Springer Nature - Complete Springer Journals</source><creator>Zulian, Francesco ; Tirelli, Francesca</creator><creatorcontrib>Zulian, Francesco ; Tirelli, Francesca</creatorcontrib><description>Purpose of Review
Treatment of scleroderma in children is challenging since little is known about its pathogenesis. Herein, we review the most recent evidence regarding the treatment of juvenile scleroderma.
Recent Findings
According to the recent recommendations for Pediatric Rheumatology in Europe (SHARE), systemic treatment in localized scleroderma is needed when there is a risk for disability, such as in generalized or pansclerotic morphea and progressive linear scleroderma. In juvenile systemic sclerosis, the introduction of the severity score, J4S, has standardized the assessment of the patients in the daily practice and allowed a more tailored therapeutic approach. Since, to date, no clinical trial is available in JSSc, due to its rarity, the treatment is based on adults’ experience.
Summary
The recent recommendations for juvenile scleroderma represent an important instrument to standardize the treatment approach, confirm the role of methotrexate, and open new windows for effective experimental treatments, such as mycophenolate mofetil and biological agents, for severe or refractory cases.</description><identifier>ISSN: 1523-3774</identifier><identifier>EISSN: 1534-6307</identifier><identifier>DOI: 10.1007/s11926-020-00910-x</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Medicine ; Medicine & Public Health ; Pediatric Rheumatology (S Ozen ; Rheumatology ; Section Editor ; Topical Collection on Pediatric Rheumatology</subject><ispartof>Current rheumatology reports, 2020-08, Vol.22 (8), p.45-45, Article 45</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-d1272bcfb930d6b81c911660300efcb1687252f651f2de0870ab1c3c2f3acfc13</citedby><cites>FETCH-LOGICAL-c324t-d1272bcfb930d6b81c911660300efcb1687252f651f2de0870ab1c3c2f3acfc13</cites><orcidid>0000-0002-2479-3485</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11926-020-00910-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11926-020-00910-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Zulian, Francesco</creatorcontrib><creatorcontrib>Tirelli, Francesca</creatorcontrib><title>Treatment in Juvenile Scleroderma</title><title>Current rheumatology reports</title><addtitle>Curr Rheumatol Rep</addtitle><description>Purpose of Review
Treatment of scleroderma in children is challenging since little is known about its pathogenesis. Herein, we review the most recent evidence regarding the treatment of juvenile scleroderma.
Recent Findings
According to the recent recommendations for Pediatric Rheumatology in Europe (SHARE), systemic treatment in localized scleroderma is needed when there is a risk for disability, such as in generalized or pansclerotic morphea and progressive linear scleroderma. In juvenile systemic sclerosis, the introduction of the severity score, J4S, has standardized the assessment of the patients in the daily practice and allowed a more tailored therapeutic approach. Since, to date, no clinical trial is available in JSSc, due to its rarity, the treatment is based on adults’ experience.
Summary
The recent recommendations for juvenile scleroderma represent an important instrument to standardize the treatment approach, confirm the role of methotrexate, and open new windows for effective experimental treatments, such as mycophenolate mofetil and biological agents, for severe or refractory cases.</description><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Pediatric Rheumatology (S Ozen</subject><subject>Rheumatology</subject><subject>Section Editor</subject><subject>Topical Collection on Pediatric Rheumatology</subject><issn>1523-3774</issn><issn>1534-6307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kLtOxDAQRS0EEsvCD1CFjsYwYyd2UqIVT61EwVJbjjNGWeWx2Ala_p4soaaaKc650r2MXSLcIIC-jYiFUBwEcIACge-P2AIzmXIlQR8ffiG51Do9ZWcxbmEiIZcLdrUJZIeWuiGpu-Rl_KKubih5cw2FvqLQ2nN24m0T6eLvLtn7w_1m9cTXr4_Pq7s1d1KkA69QaFE6XxYSKlXm6ApEpUACkHclqlyLTHiVoRcVQa7BluikE15a5x3KJbuec3eh_xwpDqato6OmsR31YzQixRxFprNiQsWMutDHGMibXahbG74NgjnsYeY9zNTS_O5h9pMkZylOcPdBwWz7MXRTpf-sH0LOYho</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Zulian, Francesco</creator><creator>Tirelli, Francesca</creator><general>Springer US</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2479-3485</orcidid></search><sort><creationdate>20200801</creationdate><title>Treatment in Juvenile Scleroderma</title><author>Zulian, Francesco ; Tirelli, Francesca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-d1272bcfb930d6b81c911660300efcb1687252f651f2de0870ab1c3c2f3acfc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Pediatric Rheumatology (S Ozen</topic><topic>Rheumatology</topic><topic>Section Editor</topic><topic>Topical Collection on Pediatric Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zulian, Francesco</creatorcontrib><creatorcontrib>Tirelli, Francesca</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current rheumatology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zulian, Francesco</au><au>Tirelli, Francesca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment in Juvenile Scleroderma</atitle><jtitle>Current rheumatology reports</jtitle><stitle>Curr Rheumatol Rep</stitle><date>2020-08-01</date><risdate>2020</risdate><volume>22</volume><issue>8</issue><spage>45</spage><epage>45</epage><pages>45-45</pages><artnum>45</artnum><issn>1523-3774</issn><eissn>1534-6307</eissn><abstract>Purpose of Review
Treatment of scleroderma in children is challenging since little is known about its pathogenesis. Herein, we review the most recent evidence regarding the treatment of juvenile scleroderma.
Recent Findings
According to the recent recommendations for Pediatric Rheumatology in Europe (SHARE), systemic treatment in localized scleroderma is needed when there is a risk for disability, such as in generalized or pansclerotic morphea and progressive linear scleroderma. In juvenile systemic sclerosis, the introduction of the severity score, J4S, has standardized the assessment of the patients in the daily practice and allowed a more tailored therapeutic approach. Since, to date, no clinical trial is available in JSSc, due to its rarity, the treatment is based on adults’ experience.
Summary
The recent recommendations for juvenile scleroderma represent an important instrument to standardize the treatment approach, confirm the role of methotrexate, and open new windows for effective experimental treatments, such as mycophenolate mofetil and biological agents, for severe or refractory cases.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11926-020-00910-x</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-2479-3485</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3774 |
| ispartof | Current rheumatology reports, 2020-08, Vol.22 (8), p.45-45, Article 45 |
| issn | 1523-3774 1534-6307 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2418125759 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Medicine Medicine & Public Health Pediatric Rheumatology (S Ozen Rheumatology Section Editor Topical Collection on Pediatric Rheumatology |
| title | Treatment in Juvenile Scleroderma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A00%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20in%20Juvenile%20Scleroderma&rft.jtitle=Current%20rheumatology%20reports&rft.au=Zulian,%20Francesco&rft.date=2020-08-01&rft.volume=22&rft.issue=8&rft.spage=45&rft.epage=45&rft.pages=45-45&rft.artnum=45&rft.issn=1523-3774&rft.eissn=1534-6307&rft_id=info:doi/10.1007/s11926-020-00910-x&rft_dat=%3Cproquest_cross%3E2418125759%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2418125759&rft_id=info:pmid/&rfr_iscdi=true |